Clinical Trial Update: A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi [Phase 3]

View source ↗

Summary

A Phase III trial evaluating buparlisib (BKM120) with fulvestrant in HR+,HER2-, AI-treated metastatic breast cancer that progressed after mTOR inhibitors was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Buparlisib (buparlisib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2019-01-09